John Wiley & Sons, Inc. Price & Performance (WLY)

Thank you, and thank you all for joining us.

On the call with me are Matt Kistner, Wiley's President and CEO Christopher Carriede, Interim CFO and Jay Flynn, Executive Vice President and General Manager of Research and Learning. Note that our comments and responses reflect management's views as of today will include forward looking statements. Actual results may differ materially from those statements. The company does not undertake any obligation to update them to reflect subsequent events. Also, Wiley provides non GAAP measures as a supplement evaluate underlying operating profitability and performance trends. These measures do not have standardized meanings prescribed by U. S. GAAP and therefore may not be comparable similar measures used by other companies. Nor should they be viewed as alternatives to measures under GAAP. Unless otherwise noted, we will refer to non GAAP metrics on the call and variances are on a year over year basis and will exclude divested assets, and the impact of currency. Additional information is included in our filings with the SEC. A copy of this presentation and transcript will be available on our Investor Relations webpage at investors.wiley.com. I'll now turn the call over to Matt Kitzner. Thank you, Brian. Good morning, everyone. Thank you for joining our third quarter update.

We continue to capitalize on the increasing demand for science John We are executing well on our objectives of driving recovery and growth in research, and material margin expansion overall. And we remain on track to achieving our outlook for this year and next in fact, we are raising our fiscal twenty twenty six margin target. For those who may be new to the story, Wiley delivers authoritative content and data driven insights to institutions, corporations, researchers and learners. Our extensive catalog includes some of the most valuable and important content in the world. Essential in the advancement of science, technology and medicine, in the responsible development of AI and other machine learning applications and in future high value use cases supporting research and development such as science analytics and information services. Let me acknowledge the economic uncertainty out there. Ranging from consumer confidence and inflation to tariffs, policy swings and geopolitical unrest. As a reminder for over two hundred years, Wiley has been a safe haven through many economic cycles and periods of disruption. We demonstrated this resiliency during the Great Recession [indiscernible] Our publishing services, content and brands remain must have Supporting this is our strong balance sheet and consistent cash generation over time as evidenced by thirty one consecutive years of dividend increases.

What makes Wiley unique and compelling over the long term?

As noted, our markets are robust. And demand remains consistent directly correlated with increasing global R and D investment. We recognize there's a wide mode business with essential authoritative content and trusted brands. We deliver resilient compounding growth in markets that remain [indiscernible] even during economic downturns. Approximately half of our revenues recurring In our research segment, this number is nearly 75%. We are in early AI in the corporate sector, particularly in research and development. Our financial characteristics are strong, with healthy margins and cash generation low leverage and ample liquidity, And finally, the leadership team at Wiley is aligned and committed to continuous improvement and value creation. Let's talk about some of the favorable underlying trends we're seeing. First, global R and D spend continues as the primary driver of research [indiscernible] Remaining strong in 2024 with growth of 8% Growth projections for 2025 are similar. Second, the demand to publish continues to increase reflecting its vital importance to the careers of researchers. Year to date, research article submissions are up 18% with publishing output up 8%, Third, our recurring revenue models demonstrate strong health with solid pricing power supported by consistently higher volume. Recurring revenue models include our subscription read only and transformational read and publish agreements.

Fourth, quality and scale matter. And Wiley excels in both areas. Quality has become more important than ever for research. As they seek to publish in trusted high impact journals At the same time scale has become more important given the increasing complexity of this mixed model ecosystem with customers ranging from individual researchers to national governments. Our top tier quality and scale give us an opportunity to have pace the market over time. Finally, Wiley's strategic position in AI development and application offers multiple advantages. As previously discussed, our content serves as a foundation for training large language models and bringing to market vertical specific LLMs. Additionally, as a publisher, the nature of our work enables us to greatly benefit from AI predict Let me shift gears and focus on our headlines for the quarter. Revenue growth was driven by mid single digit growth in research, including an expanded AI licensing project with an existing technology customer. Learning was down due to challenging comparisons to prior year as discussed in our last earnings call, and some softness in academic books. Chris will go into further detail on our segment performance.

Key takeaways from the quarter include Our calendar '25 John subscription and TA renewal season is nearly 80% complete and we are seeing encouraging growth trends. Open Access continues to demonstrate rapid growth across our journal portfolio. We expanded a corporate AI licensing agreement this quarter and continue to build a pipeline of vertical specific opportunities. It's very early days in the development of this vertical specific market. But we're seeing considerable interest from leading research intensive corporations. Margin expansion remains a multiyear strategic focus. And 50 basis points of adjusted EBITDA margin improvement over prior year. Chris will talk to our fiscal twenty twenty five outlook and fiscal twenty twenty six targets. But we see our EBITDA margin and EBS trending towards the high end of guidance and we're raising next year's margin target. Onto our results, Throughout my commentary, I'll exclude divested assets and currency impacts. Revenue was up 1% driven by research growth of 5% offsetting an expected 6% decline in learning. This year over year swing stemmed from a $6,000,000 licensing renewal the prior year and softness this quarter in academic books. Adjusted EPS increased 39% due to higher adjusted operating income and a lower adjusted effective tax rate.

Our operating margin rose two eighty basis points to 14.2% Adjusted EBITDA grew 4% reflecting revenue growth partially offset by investments in growth and productivity initiatives. Our adjusted EBITDA margin for the quarter was 23.2% up from 22.7%.

Let's talk about how we're executing on our core objectives this year.

First, driving recovery and growth in research. Year to date this segment is up 3% with growth across all key areas, including our recurring revenue models, open access publishing program, licensing and solutions. Leading indicators continue to be favorable. The expansion of our advanced journal franchise has been a great success [indiscernible] This portfolio encompasses over 20 high impact journal titles, of course disciplines, and we continue to expand in critical areas such as life sciences, AI and machine learning Our multidisciplinary journal Advanced Science is delivering exceptional growth this year.

While our newest titles Advanced Intelligent Discovery, and advanced robotics research recently published their inaugural articles We anticipate launching additional advanced journals in 2025 and 2026 And as a reminder, top tier journal franchises like Advance are differentiators for large publishers. Second, moving decisively on AI opportunities. Year to date, we've generated $30,000,000 in licensing revenue relating to trading models and executed an early but important agreement for vertical specific models. This market is evolving and our pipeline remains very active. Third, driving continued margin improvement. Through nine months, our adjusted operating margin increased three thirty basis points to 13.3% and adjusted EBITDA has improved by 160 basis points to 22.3%. Let me say a few words about the current U. S. Funding We're keeping a close eye on the potential impact of U. S. Government actions on research funding. We don't anticipate any near term impact on our research publishing programs given the exceptional volume in our article pipeline, the lead times associated with any potential impact and the recurring nature of our multiyear agreements. Importantly, as I'll describe in a moment, U. S. Federal funding only supports a small percentage of our research output. All of this is evident in today's confident reaffirmation of our fiscal twenty twenty five outlook and fiscal twenty twenty six targets, including the margin improvement, Moreover, it's too early to weigh any potential long term impact given the high level of uncertainty and the critical importance of scientific and technological activity in driving economic growth.

Peer reviewed research is how these advancements are communicated, evaluated and applied. It is referred to as the global knowledge ecosystem and Wiley stands at the center of it. Historically, this industry has advanced in good times and bad. It's always risen above politics, It's been excluded from tariffs and trade wars, and it's continued on even through conflict. It is an industry that is geographically well distributed and powered by many different funding sources. Every region participates with remarkable balance as illustrated here. For context, China leads as the number one source of research output worldwide followed by The U. S, The U. K, Germany and Japan. Governments in these countries consider this positioning strategically important contributing to Wiley's broad geographic diversification regional breakouts, Asia Pacific is responsible for around 45% of EMEA around 30%, North America around 20%, and other makes up about 5%. As for The U. S, direct federal funding is only responsible for a single digit percentage of our total article output Of course, we are fully confident that The U. S. Scientific technical and medical research will continue to receive federal support given the essential role that research plays in U. S. Economic growth, global competitiveness, and societal well-being.

Where are we today? Mature markets have returned to steady growth supported by continued R and D investment, and growth markets have seen some remarkable new developments. Consider India's innovative one day We recently executed this multiyear agreement expanding access to over 6,000 Indian institutions and supporting 18,000,000 researchers and students While this expansion increases profitable revenue for us Its significance extends beyond financial metrics. The agreement unifies the research ecosystem of the world's second most populated country And as our India country lead, Ritesh Kumar stated, it empowers Indian researchers to lead global scientific conversations and accelerate the country's research output. Our presence in India positions us well as these initiatives drives progress, and growth in Indian research, Similarly, in Brazil, we see expands access to over four thirty research academic institutions. Reaching upwards of 6,000,000 researchers, Both these landmark agreements serve strategic purposes that transcend immediate financial benefits They expand access in emerging growth markets. And deliver additional revenue streams and ultimately enlarge both the scientific community and the global supply of quality research. Let's examine R and D and publication funding. Which shows similar geographic diversification. Our institutional models draw support from a diverse range of funding sources including national governments such as our single licenses in Germany and India, national funding bodies and agencies, state governments, private endowments, foundations, tuition revenue, and corporations I'll emphasize again that nearly 75% of our research published revenue is recurring.

Also, while many associate U. S. R and D with federal government funding, corporations fund 80% of total U. S. R and D investment. This reality reveals one of our most promising long term opportunities. Currently, corporations represent a relatively small percentage of our overall revenue. However, we believe there is significant sustained value in integrating our content and data more deeply into the corporate research process such as AI, model enablement and providing data and analytics to support the research process. Taken together, all these factors position research as both resilient and poised for continued expansion. To summarize, we continue to see growth this year in our recurring models and open access program. Renewals and leading indicators are favorable and give us strong visibility. Over the long term, our quality and scale will remain essential elements for attract and retaining research authors and driving market share gains. Let's now turn to AI growth. Particularly the long term corporate opportunity I mentioned earlier. This quarter, we executed an expanded agreement for AI model training purposes and we're seeing promising developments in the broader vertical specific market. The agreement builds on the project announced in Q1 involving back listed learning content for training large language models.

This Q3 expansion incorporates backlist research content defined as previously published material older than three years. The $9,000,000 agreement brings our total AI revenue this year to $30,000,000 following $23,000,000 realized last year. As a reminder, these Phase one trading agreements are John It's important to reemphasize that licensing represents a core business activity for Wiley. As we take on new AI specific initiatives, our guiding principles remain straightforward. We recognize our responsibility to engage with AI developers to secure scientific accuracy and deliver optimal learning outcomes. These models require training John trusted authoritative contents while protecting the rights of authors and other copyright holders. A fundamental responsibility we embrace as a knowledge company. Beyond these large scale training agreements, we're seeing encouraging demand from multinational R and D centric companies, of course critical biopharmaceuticals and industrial chemistry. Distinct from our LLM training agreements, these R and D intensive corporations are using AI powered content and tools to speed up product development, identify breakthroughs, and reduce internal cycle times. And although the individual opportunities are materially smaller in size, they represent a much larger address and the revenue is highly likely to be recurring. [indiscernible] phase two of our content licensing strategy.

With a broad set of applications across the many disciplines we [indiscernible] These types of collaborations would extend beyond generating new licensing revenue streams to function as strategic partnerships enabling mutual learning about AI application development and its impact on improving research outcomes. The market will take time to fully develop, but we are in encouraged by the early demand we're seeing. I'll now pass the call to Chris to take you through our year to date results, segment performance Outlook and financial position.

Thank you, Matt, and good morning, everyone. Our results continue to align with expectations.

Reinforcing our confidence in achieving our fiscal twenty twenty five outlook and fiscal twenty twenty six targets. Which I'll speak to shortly. Turning to our year to date results, adjusted revenue grew 3% driven by core growth in research and AI licensing. Excluding one time AI related revenue, overall revenue grew 1%. With research increasing 2%. We continue to advance our margin expansion initiatives resulting in significant improvements. Adjusted operating income up 38% EPS up 43% and EBITDA up 12%. Our adjusted operating margin improved by three thirty basis points to 13.3% and our adjusted EBITDA margin rose 160 basis points to 22.3%. We continue to focus on optimizing our cost structure more specifically rightsizing our technology costs and other corporate expenses. At the same time, we're transforming how we publish and work to drive greater operating efficiency. We do anticipate restructuring charges from this activity. Meanwhile, free cash flow shows strong recovery and we remain on track to achieve $125,000,000 in fiscal twenty twenty five. Turning to our Research segment, third quarter and year to date revenue increased 53% respectively. Q3 growth stemmed primarily from AI licensing, and our open access programs.

For the nine month period, research publishing growth reflected strong demand to publish and read. With double digit growth in gold open access, and low single digit growth in our recurring revenue models, offsetting softness in ancillary products. A reminder that ancillary products include print, and other non recurring items such as [indiscernible] article pay per view, digital archives, and title by title journal sales to libraries. Onetime AI licensing projects for backlisted content worth approximately $10,000,000 year to date also contributed to our year to date results. Excluding these AI projects, research revenue is up 2% year to date. As Matt mentioned, we have completed nearly 80% of our calendar 2025 renewal season and see steady growth trends. The multiyear nature of these agreements means that around one third of our library customers and consortia come up for renewal annually. We have successfully renewed major agreements in The UK, France, and The U. S. While executing those new landmark deals in India, [indiscernible] This renewal season extends from early December through the April 2025. Research Solutions has successfully returned to growth.

With revenue increasing 6% in the quarter and 3% year to date. Driven by expanded content solutions, and databases for societies, corporations, and other publishers. Wiley's key differentiator continues to be our enduring success in partnering with societies and other professional organizations. Four of our key society health science partners have been with us for over fifty years. Up 45% have been with us for more than twenty.

This remarkable retention rate demonstrates not only our shared success but also highlights one of our most valuable assets, our reputation. Partnerships like these are becoming increasingly multidimensional, with Wiley delivering a comprehensive suite of services from publishing and content platforms to marketing and recruitment, Our IAAA partnership exemplifies this approach.

As one of the world's largest societies responsible for a third of all tech literature, in electrical engineering and computing John, IEEE now benefits from Wiley's expanded role in managing their advertising sales and programs. This arrangement provides access to highly engaged audiences through impactful advertising, and digital content solutions. For Wiley, this partnership extends our participation in the engineering vertical leveraging our unique access to one of the world's most valuable professional audiences, [indiscernible] Adjusted EBITDA for research increased 12% for the quarter and 5% year to date. Reflecting revenue growth, and cost savings partially offset by investments in growth and productivity. Our Q3 margin improved by 180 basis points to 32.7% while our year to date margin improved by 30 basis points to 31.1%. In summary, we are encouraged by our Q3 and year to date performance in research, and continue to anticipate a strong finish to the year. Let me now address our Learning segment. In addition to challenging year over year comparisons, we saw moderate softness in academic book sales. While Q3 revenue decreased 6%, year to date revenue rose 4%. Driven by expansion in professional content, and AI licensing revenue. We continue to experience robust growth in signing new book titles across the science, technology, medicine and professional fields.

Additionally, our XiBook STEM courseware remains a strong growth driver.

Adjusted EBITDA for the Learning segment decreased 5% this quarter reflecting revenue performance. Nevertheless, our margin expansion initiatives delivered 30 basis points of improvement resulting in an adjusted EBITDA margin of 35.4% John. Year to date, our margin for learning improved by over 400 basis points. To 35.3%. In summary, the year over year softness in Q3 aligned with our expectations. We continue to secure new business in our core areas, enhance margins, and engaged in productive licensing discussions with AI developers. Turning to corporate unallocated expenses. These decreased 5% this quarter primarily due to lower Excluding D and A, expenses increased 9% reflecting the timing of investments in enterprise modernization, and consulting fees related to strategic initiatives including reengineering our cost structure, Notably, our segment margins improved both this quarter and year to date partly resulting from our reduced corporate allocated expenses.

This demonstrates our continued progress in rightsizing our shared service costs and we have additional improvements planned.

Let me now turn to our growth outlook. Our year to date execution, performance and indicators remain solid. Enabling us to reaffirm our outlook in the mid to high end of our projected ranges. As previously noted, we anticipate a strong Q4 for our Research segment driven by favorable journal renewals, and demand to publish indicators, as well as accelerating growth in research solutions and favorable comparisons to prior year. These positive factors should more than offset the $23,000,000 non recurring AI deal recorded in Q4 of last year Also as mentioned earlier, we are reassessing our cost structure with additional expected savings expected in fiscal 'twenty six. To summarize, we expect full year revenue to land near the midpoint of our $1,650,000,000 to $1,690,000,000 range. Representing top line growth of approximately 3%. Our segment outlook aligns with expectations with research revenue growing by low to mid single digits and learning by low single digits.

Adjusted EBITDA is expected to land near the midpoint between $385,000,000 to $410,000,000 translating to high single digit growth. We anticipate our EBITDA margin to be at the high end of our 23% to 24% range.

Adjusted EPS is to be at the high end of our $3.25 to $3.6 range. Delivering strong double digit growth over last year's $2.78 Finally, free cash flow is expected to meet our guidance of approximately $125,000,000 an improvement from $114,000,000 in the prior year.

While capital expenditures will come in lighter than initially projected, restructuring costs will be higher due to expanded cost reduction initiatives. Let's turn to the targets we first set down in January of Since that point, we've made decisive moves to improve our fundamentals and will continue to do so. Given our momentum in investments in research, our improved efficiency and additional cost savings we are increasingly confident of our outlook for fiscal 'twenty six. One, we continue to see revenue growth in the low to mid single digit range. Two, we are raising our margin target to be above 25%.

From the original 24% to 25% range. We will be more specific when we discuss our full year guidance in June John.

Three, we are reaffirming our free cash flow target of $200,000,000 up from $114,000,000 in fiscal twenty twenty four and 125,000,000 projected for fiscal twenty twenty five. Let me walk you through the basic components of that improvement. As is illustrated here, we anticipate strong EBITDA growth Next year, given our revenue and margin outlook, lower restructuring costs, and improved working capital. Let me briefly conclude with our financial position and return to shareholders. Cash flow from operations and free cash flow year to date are much improved due to a mix of improved operating performance and working capital timing. Free cash flow year to date has benefited from lower CapEx. Year to date, we continue to return cash to shareholders. With dividends and share repurchases totaling $93,000,000 up from $87,000,000 in the prior year.

Approximately 35,000,000 was used to acquire 784,000 shares our current dividend yield is over 3.5%. Finally, our net debt to EBITDA ratio was two point zero at the January John, compared to 1.9 in the prior year period. The more appropriate time to look at this number is when we report April year end in June John. Last year we disclosed a leverage ratio of 1.7.

With that, I'll pass it back to Matt.

One final mention before I summarize our key takeaways. Yesterday, we announced that Doctor. Karen Madden has joined the Wiley Board of Doctor. Madden is the Senior Vice President and Chief Technology Officer at Millipore Sigma, the U. S. And Canada Life Science business of Merck KGaA.

Where she is responsible for shaping the technology roadmap and R and D strategy. Millipore Sigma, develops products focused on scientific discovery biomanufacturing and testing services. As noted, Wiley's long term strategy is increasingly focused on the corporate R and D value chain and Doctor. Madden's wealth of knowledge and expertise in this area will be a tremendous addition. Okay. Let's review our key takeaways before we move on to questions. In periods of economic uncertainty, Wiley has consistently served as a safe haven delivering resilient compounding growth across economic cycles and displaying geographic diversification significant competitive advantages and strong financials. We will continue to move forward with operational discipline, fiscal prudence and strategic foresight. We are an early beneficiary in AI development evolving alongside our corporate partners. We continue to explore various content opportunities for training, inference and application with an encouraging pipeline. As emphasized, content licensing represents a core business activity for us not merely an AI specific initiative. Our execution remains strong with excellent organizational alignment yielding significant year to date improvements in both margins and cash flow and we maintain full confidence in our outlook for Q3 fiscal twenty twenty five and fiscal twenty twenty six, with margin upside and a reaffirmed free cash flow target, of $200,000,000 I want to thank all of you for your interest and time today.

I also extend my sincere appreciation for their dedication and hard work in bringing us to this point and positioning us for even greater success in the future. I'll open the floor for questions.

Your first question comes from the line of Daniel Moore with C JF Securities. Please go ahead.

Yes, thanks. Good morning, Matt. Good morning, Chris. Thanks for all details and color. Great to see the progress and upward revision regarding the 26 margin target. Maybe just talk a little bit about the drivers. Is it additional cost savings? Incremental confidence on revenue, AI expectations for incremental AI revenue, all the above, just driving upward Revision there.

Thanks, Dan, and let me kick it off and then I'll turn it over to Chris, but it's it's really primarily driven by working on the cost structure. It's really gratifying to see the ability to John confidence really talk about these improvements coming through in our guidance. But really across the organization, we've been hard at work at Let's say rationalizing the structure and And getting back to what we would consider competitive margin levels, Let me turn it over to Chris who can give you a little more insight into that. Yes. Thanks, Matt.

Dan, primary driver as Matt said is that we are rationalizing our cost structure largely in corporate shared services. We've been signaling that we were focused on this area We see that we will begin execution on that and the latter part of this year, you'll see the benefit next year. It's 100 plus basis point improvement we expect as a result of the actions we're Really helpful. And Just real quick, we want to create sustainable value here in terms of what I would call permanent margin improvement. So make these actions we're taking really count. So really of course the organization we're looking at at the structure of footprint in certain places and and really looking at getting excited at not only 26, but even beyond to be showing really a continuous improvement mindset around margins.

I think you just took the next question out of my mouth. Thinking about the longer term opportunity, what have you learned from competitors Springer now that they're public, how do you compare and contrast your cost structure and how you think about the potential for more sustained margin upside going forward?

Yes, we did a lot of benchmarking including of course our competitors at Springer Nature and it did point us to looking at structural cost differences. Now you do know that there are mix of business is quite different from us. So they do we do have more of a society business in our mix than they do.

So that has the royalty costs associated with it. But even when you back out the royalty cost, it points us in the direction that we do have an opportunity opportunity to streamline our cost structure. So So I think and we talked about this both with the executive team and the broader team here and we are all Looking at margin improvement as kind of a way of life, I think there is A lot of room for improvement there, but we want to do it in the right way and interfere with the work we're doing on driving revenue growth Understood. Very helpful. Switching gears, the $9,000,000 increase dollars incremental AI revenue, just to confirm that the full $9,000,000 fell in Q3 and that was in research as opposed to the prior agreements which fell into learning, correct?

That's correct, Dan. You have that right. [indiscernible] That's perfect. Switching gears again in terms of learning, obviously, you had a tough comp this quarter. Just talk about the outlook over the next say, twelve months plus, both academic and professional sides of the business and your confidence in getting back to positive growth in fiscal twenty twenty six given some of the tougher comps be up against particularly in the first half of the year?

Well, let Ajay is on the call, so let him talk a little bit of kind of how he's looking at the business outlook and then Chris can give you a sense of the numbers. Thanks Matt and Dan. To Nice to hear from you again. So We did indeed have a tough comp. I think if you exclude the AI revenue though, from the last quarter, we were only off about [indiscernible] in terms of prior year. And that points to some timing in the business a little bit of pressure in the retail channel. And specific assumption around enrollments in the fall and spring semesters that just proved a little ambitious.

In terms of where we wanted to be this year.

Overall, I think The things I'd point to that give us some optimism and really underpin The essence of what Matt was talking about and what we're doing, point to improve margin in learning in the quarter as a key driver of that overall margin mix improvement that we're looking at. Growth in our our XiBooks business underlying Courseware and a real long term opportunity and continued digital licensing and AI in that business that we're looking to capitalize on. So just to reiterate, We think that improved cost discipline, efficiency measures supporting higher margins remain a key feature in the business and that we've got a nice mix of products there that is in the in both the short and medium term, John to continue to do its job for us in the P and L and help support our overall guidance. Chris, you want to add, Nick?

Yes, if I could. I don't want to specifically get into projections into 2026, but I'll just say relative to this Q4, We do have a tough comp coming up Obviously, last year, we had large [indiscernible] If we remove out that deal, we would actually be talking about a very positive learning growth in Q4. Instead, we we only see it coming down in the low to mid single digits. In Q4. And a lot of that is strength as Jay alluded to in Courseware a big quarter for Courseware. And it will have an impact there. And also there are other licensing deals that we anticipate will mitigate to some degree the large deal that we had in the prior year. Does that answer your question, Dan?

It does. That's helpful. And you alluded to the strength in some of the book signings, the author signings, etcetera. So it should bode well for fiscal 'twenty six. Maybe one more. Obviously, bought back I think, dollars 35,000,000 in the quarter. You're looking at given the guidance somewhere in the over the next call it five quarters, you'll generate $335,000,000 plus of revenue of free cash flow.

And that's obviously pre dividend, but still significant opportunity and leverage keeps going lower. So just talk about capital allocation near term stocks trade in sub-ten times earnings, how you're thinking about buybacks versus paying down debt and any other uses of of your cash flow? Thanks again for all the color.

Sure.

Yes, In the current year, we've been buying back at a larger excuse me, a higher rate than we had in prior year.

It's modest to some degree, but so is our cash flow improvement. Year over year.

As we expand into the next year, we'll be taking a hard look at The pace of our share repurchases there's no commitments at this point, but obviously we'll have more free cash flow to to make that assessment. Anything else, Dave? Okay. Operator, can you prompt again?

Your next question comes from the line of Sami Casan with BNP Paribas. Please go ahead. Thank you very First one, you describe Sam, you're breaking up. Can we better now? [indiscernible] So you described how The U. S. Already accounted for 20% of your Arctic Cup count.

You a little bit elaborate John your revenue exposure to U. S. Institutions and in particular to U. S. Medical [indiscernible] Given all the talks around NIA trending, The second question I may could you give a few examples of deploying AI internally helps improve cost efficiency? And can we discuss whether thanks to AI and tools, productivity gains can help improve margins. Are we talking about AI driving 10 John or are we talking about AI and automation driving 100 bps or more?

Yes, I don't think we're going to get to I'm sorry, Sami, go ahead. And lastly, when I look at Elsevier, Elsevier or Springer or Informa, their research business is growing 4% to 5% organically. Do you think that research can accelerate towards 4%, five in the short to medium term or other structural differences in exposure that perhaps may prevent that in the medium term.

Thank you very much, Jeff. Yes. Let me Let me try to answer all of that and I'm going to ask Jay to step in at the right time. On the last question, you may have heard us on the prior call talk about the fact that we have a lot of our research revenue back ended this year into the fourth quarter. You'll see that when we finish the year, we'll be research growth rates will be much more at industry levels. So that's the answer to the last question. John the percentage, as you might imagine, we're monitoring the developments in The U. S. Very carefully. And when we look at the impact of some of the potential impact of some of The U. S. Funding actions it really traces back to a low single digit impact on us And there are also, as you all know, Many of these arrangements we have are in multiyear agreements and there are time lags associated with the impact and the fact is right now there were so many unknowns with how this is going to fall out in terms of policy changes and court challenges. So we're very confident about the business given its geographical diversification, I'll add John to that.

So we're confident and confident enough to reaffirm our guidance.

So but we are monitoring it and taking it very seriously. On the middle question about the AI impact, on kind of how we run the business, Jay and his team have some very, very exciting things underway. And we don't we don't translate it into a particular financial impact at this point, but it's part of what's driving the overall margin improvement in the company that we're committing to with our increased margin guidance But Jay, maybe touch on a couple of interesting areas where you're finding good Yes. Sure, Matt. And Sami, thanks for the question. And thanks for the interest, of course.

Let me just Before I jump into AI, you asked about U. S. Medical Library exposure. I just want to reiterate one of the two things that Matt said. In the prepared remarks talked about how 84% of our content comes from outside The United States. And that distribution of articles only it's a single digit number that's tied directly to federal funding. And of course, we anticipate a strong year as Chris talked about as we put in our guidance.

Specifically with medical libraries, I recall correctly, there's about 120 academic medical centers in The United States. We have thousands of customers globally. And so while of course we're monitoring what happens at those medical centers and in those medical libraries.

We feel good about A, the relationships long term that we have with those customers and b, we feel good about the global nature of the business. So on that, let me just pivot to the question a bit more. And as Matt points out, we are really We feel like we are driving and embracing AI both in the innovation side of the business and in the cost savings side. And you asked particularly about opportunities in cost. Certainly workflow automation document review, research integrity, automation of content workflows in particular are areas where we're spending a lot of time. We've got a group set up internally called the Magic Lab that we've point at this kind of work and they're working every day with both inside the building and outside the building. We're bringing in experts to help us on this journey. But we feel really We feel very optimistic [indiscernible] two things. One, humans are going to stay at the center of the AI work in our [indiscernible] because of the importance of human and expert overview and review of the processes, And second, we feel like This is an area where we want to lead and we want to continue to invest.

And so maybe as the key takeaway Tammy, I think our approach is ensuring that AI innovation is going to happen with integrity, and we're going to balance technology process with ethical stewardship, author engagement and [indiscernible] just a laser like focus on both the top and the bottom line.

Thank you very much. Very helpful. Thank you. Thank you, Sammy.

Again, If there are no other questions, operator, I can wrap up.

I will turn the call back over to Mr. Gisner for closing remarks.

Thank you.

Well, thank you everyone. We appreciate you spending time with us. We appreciate your confidence Again, I want to thank the Wiley colleagues around the world who have helped drive this terrific progress we're seeing and we look forward to catching up with all of you again in June when we talk about the close of the fiscal year. Have a great day.

Ladies and gentlemen, that concludes today's call.